Retatrutide iri kubuda yakawanda-receptor agonist, inonyanya kushandiswa kurapa kufutisa uye metabolic zvirwere. Inogona kuita panguva imwe chete matatu incretin receptors, kusanganisira GLP-1 (glucagon-like peptide-1), GIP (glucose-inotsamira insulinotropic polypeptide) uye glucagon receptor. Iyi nzira yakawanda inoita kuti retatrutide iratidze kugona kukuru mukutonga uremu, kudzora shuga yeropa uye hutano hwese metabolic.
Zvimiro uye mhedzisiro ye retatrutide:
1. Nzira dzakawanda dzekuita:
(1) GLP-1 receptor agonism: Retatrutide inosimudzira insulin secretion uye inhibits glucagon kusunungurwa ne activating GLP-1 receptors, nokudaro zvichibatsira kuderedza shuga yeropa, kunonoka kubuda mudumbu uye kuderedza kudya.
(2) GIP receptor agonism: GIP receptor agonism inogona kuwedzera kuvharirwa kwe insulini uye kubatsira kuwedzera kuderera kweshuga yeropa.
2. Glucagon receptor agonism: Glucagon receptor agonism inogona kukurudzira kuora kwemafuta uye simba remetabolism, nokudaro zvichibatsira kuderedza uremu.
3. Huremu hunorema hunoita: Retaglutide yakaratidza hukuru hwekurasikirwa nemigumisiro mune zvidzidzo zvekliniki uye inonyanya kukodzera kune varwere vakaoma kana varwere vane metabolic syndrome. Nekuda kwemaitiro ayo akawanda echiito, ine basa rakatanhamara mukuderedza mafuta emuviri uye kudzora uremu.
4. Kudzora shuga yeropa: Retaglutide inogona kunyatsodzikisa mazinga ehuga uye inonyanya kukodzera kune varwere vane chirwere cheshuga chechipiri vanoda kudzora shuga. Inogona kubatsira kuvandudza insulin senitivity uye kuderedza postprandial shuga yeropa kuchinja.
5. Kugona kwehutano hwemwoyo: Kunyange zvazvo retaglutide ichiri muchikamu chekutsvakurudza kwekliniki, ruzivo rwekutanga runoratidza kuti inogona kunge iine mukana wekuderedza njodzi yezviitiko zvemwoyo, zvakafanana nekuchengetedzwa kwemwoyo kune mamwe mishonga yeGLP-1.
6. Injection administration: Retaglutide ikozvino inoshandiswa nejekiseni ye subcutaneous, kazhinji sekugadzirwa kwenguva refu kamwechete pavhiki, uye iyi dosing frequency inobatsira kuvandudza kutevedza kwevarwere.
7. Mamiriro ezvinhu: Migumisiro inowanzoitika inosanganisira zviratidzo zvemudumbu zvakadai sekusvotwa, kurutsa uye manyoka, zvakafanana nemigumisiro yemamwe mishonga yeGLP-1. Zviratidzo izvi zvinowanzoonekwa mumatanho ekutanga ekurapa, asi varwere vanowanzogadzirisa zvishoma nezvishoma sezvo nguva yekurapa inowedzera.
Clinical research uye kushandisa:
Retaglutide ichiri kuita miyedzo mikuru yekiriniki, kunyanya kuongorora mhedzisiro yayo yenguva refu uye kuchengetedzeka mukurapa kufutisa. Kwekutanga mhedzisiro yekuongororwa kwekiriniki inoratidza kuti mushonga une chekuita nekurasikirwa nehuremu uye nekunatsiridza hutano hwemetabolism, kunyanya kune varwere vane mashoma maitiro emishonga yechinyakare.
Retaglutide inoonekwa serudzi rutsva rwepeptide mushonga une mukana mukuru wekushandisa mukurapa kufutisa, metabolic syndrome uye Type 2 chirwere cheshuga. Nekuburitswa kwedhata rekiriniki rekuyedza mune ramangwana, zvinotarisirwa kuve mumwe mushonga wekubudirira wekurapa kufutisa uye metabolic zvirwere.
Nguva yekutumira: May-27-2025